Tecentriq-Avastin combo poised to become SOC for hepatocellular carcinoma

Tecentriq continues to carve out a niche in the crowded PD-1/PD-L1 space as new survival data for the drug in the combination with Avastin in hepatocellular carcinoma pave the way for the regimen to become standard of care.

On Friday, Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit unveiled data from the Phase III IMbrave150 study showing the combination of Tecentriq atezolizumab and Avastin bevacizumab met the co-primary endpoints of improvement in median overall survival (OS) and median progression-free survival (PFS) vs. standard-of-care Nexavar sorafenib in first-line unresectable HCC. ...